Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.44 |
| ▸ | CBFB | Q13951 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390917 | 1.00 | PDK1 (0.58) | PDK1POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL13053007 | 0.77 | NPC1 (0.52) | PDK1POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL13052988 | 0.77 | NPC1 (0.52) | PDK1POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL30190003 | 0.77 | PDK1 (0.60) | PDK1POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL140126 | 0.77 | PDK1 (0.60) | PDK1POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL23643784 | 0.75 | POLB (0.41) | PDK1POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL21788715 | 0.75 | POLB (0.44) | PDK1POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL137507 | 0.75 | PDK1 (0.58) | PDK1POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL2642887 | 0.75 | PDK1 (0.58) | PDK1POLBNPC1SMN1; SMN2RAB9A | |
| SCHEMBL369133 | 0.75 | PDK1 (0.58) | PDK1POLBNPC1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| WO-2024118488-A1 | 2-PHENYLMORPHOLINE AND 2-PHENYL(THIO)MORPHOLINE COMPOUNDS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-02-13 | — | — | US | disclosed |
| US-11829036-B2 | Optically anisotropic multilayer product and method for producing same | ZEON CORPORATION (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20230357188-A1 | PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230322754-A1 | IRAK INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4242198-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS XIV | BASF SE (DE) | 2023-09-13 | — | — | EP | disclosed |
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | AC IMMUNE SA (CH) | 2023-08-17 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| US-5472964-A | Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1995-12-05 | — | — | US | disclosed |
| US-5385897-A | 3-(3-quaternary ammonium prop-1-enyl), 7-((2-(aminothiazol-4-yl), 2-(alkoxyimino)acetamido)-3-isocephems; penicillin-resistant staphylococcus | ROUSSEL-UCLAF (FR) | 1995-01-31 | — | — | US | disclosed |
| WO-1994014815-A1 | DIARYL 5,6-FUSEDHETEROCYCLIC ACIDS AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1994-07-07 | — | — | WO | disclosed |
| EP-0604114-A1 | Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1994-06-29 | — | — | EP | disclosed |
| EP-0232623-B1 | 1-CARBACEPHALOSPORIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0214029-B1 | 1-DETHIA-2-THIA CEPHALOSPORANIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1992-03-25 | — | — | EP | disclosed |
| US-4892942-A | 1-CARBA (DETHIA)CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1990-01-09 | — | — | US | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0214029-A1 | 1-Dethia-2-thia cephalosporanic-acid derivatives, process for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1987-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255976-A1 | Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates | MAPT, MAP1LC3A, MAP1LC3B | PDK1 2804/4885POLB 2923/4885NPC1 290/4885 |
| US-20230322754-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PDK1 794/4885POLB 2535/4885NPC1 1962/4885 |
| US-20230357188-A1 | PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF | AHR, ORAI3, WNT3 | PDK1 3363/4885POLB 2432/4885NPC1 2396/4885 |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | TK2, TYMP, DPYD | PDK1 49/4885POLB 2315/4885NPC1 2300/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | PDK1 924/4885POLB 2645/4885NPC1 2546/4885 |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | PDK1 924/4885POLB 2645/4885NPC1 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.